BPC-157: Safety, Legal Status, and Human Evidence

BPC-157 is a 15-amino-acid peptide. Its originating research group at the University of Zagreb describes it as a stable gastric pentadecapeptide. It is popular among athletes for musculoskeletal injury recovery, even though it has no regulatory approval for human use.

BPC-157 is investigational. No regulator in the United States or Canada has approved it for any use, so no approved product exists whose quality and safety have been reviewed for people.

In rats, BPC-157 sped the healing of experimental colon and skin defects and closed colocutaneous fistulas, whether it was given in drinking water or by injection. The authors examined how this effect relates to the nitric-oxide system. In another rat study, treatment after experimental spinal cord injury was followed by better tail motor function and less loss of nerve tissue. The same group reports anti-inflammatory effects in animals and effects on several molecular pathways.

These are animal findings. How BPC-157 acts in people has not been established. Both cited rat studies come from the Zagreb group (Sikiric, Seiwerth and colleagues), and independent replication by unaffiliated laboratories is limited.

A 2026 systematic review in Acta Orthopaedica Belgica searched four databases up to June 2026 for human studies of BPC-157 for any use. It found three small studies without control groups, 30 participants in total: a retrospective study in knee pain, a retrospective pilot in interstitial cystitis, and a prospective safety pilot in two people. All three reported symptom improvement in most participants and no treatment-related adverse events. The reviewers judged each study to be of poor quality and rated the overall certainty of evidence as very low.

Without comparison groups, these reports cannot show that BPC-157 caused the improvements. The reviewers concluded that BPC-157 should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials.

One randomized, double-blind, placebo-controlled phase 2 trial in MRI-confirmed hamstring strain is registered on ClinicalTrials.gov. It is sponsored by a company, began recruiting in 2026, and has no results yet. An older inflammatory bowel disease program (PL-14736) is often cited as human proof, but its results were never published in a peer-reviewed journal.

Human safety is not established. The three small human studies reported no treatment-related adverse events, but samples this small cannot establish safety. Long-term effects in people are unknown.

FDA says compounded drugs containing BPC-157 may carry a risk of immune reactions to the peptide (immunogenicity) for some routes, and may raise problems with peptide-related impurities and characterization of the active ingredient. FDA also says it has no, or only limited, safety information for the proposed routes.

How BPC-157 is absorbed and cleared in people has not been measured in the cited studies, and human oral bioavailability is uncharacterized.

BPC-157 is not approved by the FDA or Health Canada and remains investigational. WADA names it in section S0 of the Prohibited List, which covers substances with no current approval by any government health authority for human therapeutic use. Substances in S0 are prohibited at all times, in and out of competition. The NCAA also names BPC-157 on its banned substances list.